• Fulcrum Therapeutics and Slate Medicines agreed November 7, 2026, to sell Fulcrum's early-stage fetal hemoglobin assets for approximately $7 million cash.
• The buyer is an unaffiliated pharmaceutical company.
• Closing depends on completion of the proposed Slate merger under the August 16, 2026, agreement, or necessary approvals if that agreement terminates.
• Proceeds are expected to enter escrow before the merger closes, count toward merger net cash and increase the expected cash dividend.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-458387), on November 12, 2026, and is solely responsible for the information contained therein.